BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Drost CC, Rovas A, Osiaevi I, Rauen M, van der Vlag J, Buijsers B, Salmenov R, Lukasz A, Pavenstädt H, Linke WA, Kümpers P. Heparanase Is a Putative Mediator of Endothelial Glycocalyx Damage in COVID-19 - A Proof-of-Concept Study. Front Immunol 2022;13:916512. [PMID: 35757776 DOI: 10.3389/fimmu.2022.916512] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin 2022. [PMID: 36253560 DOI: 10.1038/s41401-022-00998-0] [Reference Citation Analysis]
2 Solimando AG, Marziliano D, Ribatti D. SARS-CoV-2 and Endothelial Cells: Vascular Changes, Intussusceptive Microvascular Growth and Novel Therapeutic Windows. Biomedicines 2022;10:2242. [DOI: 10.3390/biomedicines10092242] [Reference Citation Analysis]
3 Zechendorf E, Schröder K, Stiehler L, Frank N, Beckers C, Kraemer S, Dreher M, Kersten A, Thiemermann C, Marx G, Simon T, Martin L. The Potential Impact of Heparanase Activity and Endothelial Damage in COVID-19 Disease. JCM 2022;11:5261. [DOI: 10.3390/jcm11185261] [Reference Citation Analysis]